PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21839782-10	2011	These results suggest that disruption of Igf-1/Akt signaling is a causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells are protected by maintaining Igf-1/Akt signaling.	Simvastatin	86-97	insulin-like growth factor 1	Mus musculus	41-46	
17327694-0	2007	Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner.	Simvastatin	0-11	insulin-like growth factor 1	Mus musculus	20-48	
17327694-2	2007	In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells.	Simvastatin	46-57	insulin-like growth factor 1	Mus musculus	112-140	
17327694-2	2007	In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells.	Simvastatin	46-57	insulin-like growth factor 1	Mus musculus	142-147	
17327694-6	2007	After induction of differentiation in the presence of 1 microM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased.	Simvastatin	63-74	insulin-like growth factor 1	Mus musculus	87-92	
17327694-7	2007	Although mRNA expression of the IGF-1 receptor beta-chain (IGF-1R beta) did not change, protein level of the 200 kDa IGF-1Rbeta precursor was significantly increased by simvastatin in a dose-dependent manner.	Simvastatin	169-180	insulin-like growth factor 1	Mus musculus	32-37	
17327694-9	2007	These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rbeta in an HMG-CoA reductase inhibition-independent manner.	Simvastatin	27-38	insulin-like growth factor 1	Mus musculus	49-54	
27734117-0	2017	IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes.	Simvastatin	15-26	insulin-like growth factor 1	Mus musculus	0-5	
27734117-5	2017	C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis.	Simvastatin	44-55	insulin-like growth factor 1	Mus musculus	114-119	
27734117-5	2017	C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis.	Simvastatin	88-99	insulin-like growth factor 1	Mus musculus	72-77	
27734117-5	2017	C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis.	Simvastatin	88-99	insulin-like growth factor 1	Mus musculus	114-119	
27734117-7	2017	In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1.	Simvastatin	13-24	insulin-like growth factor 1	Mus musculus	77-82	
27734117-7	2017	In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1.	Simvastatin	13-24	insulin-like growth factor 1	Mus musculus	121-126	
27734117-8	2017	Nevertheless, simvastatin-induced myotoxicity could be at least partially prevented by IGF-1.	Simvastatin	14-25	insulin-like growth factor 1	Mus musculus	87-92	
27734117-13	2017	IGF-1 can prevent simvastatin-associated cytotoxicity and metabolic effects on C2C12 cells.	Simvastatin	18-29	insulin-like growth factor 1	Mus musculus	0-5